QURE
Price
$13.88
Change
-$0.35 (-2.46%)
Updated
Jun 27, 04:59 PM (EDT)
Capitalization
759.91M
33 days until earnings call
ZVRA
Price
$9.00
Change
-$0.28 (-3.02%)
Updated
Jun 27, 04:59 PM (EDT)
Capitalization
492.12M
52 days until earnings call
Interact to see
Advertisement

QURE vs ZVRA

Header iconQURE vs ZVRA Comparison
Open Charts QURE vs ZVRABanner chart's image
uniQure
Price$13.88
Change-$0.35 (-2.46%)
Volume$16.03K
Capitalization759.91M
Zevra Therapeutics
Price$9.00
Change-$0.28 (-3.02%)
Volume$29.17K
Capitalization492.12M
QURE vs ZVRA Comparison Chart in %
Loading...
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
QURE vs. ZVRA commentary
Jun 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is QURE is a Hold and ZVRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 28, 2025
Stock price -- (QURE: $13.88 vs. ZVRA: $9.00)
Brand notoriety: QURE and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: QURE: 52% vs. ZVRA: 203%
Market capitalization -- QURE: $759.91M vs. ZVRA: $492.12M
QURE [@Biotechnology] is valued at $759.91M. ZVRA’s [@Biotechnology] market capitalization is $492.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

QURE’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • QURE’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, ZVRA is a better buy in the long-term than QURE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

QURE’s TA Score shows that 3 TA indicator(s) are bullish while ZVRA’s TA Score has 4 bullish TA indicator(s).

  • QURE’s TA Score: 3 bullish, 6 bearish.
  • ZVRA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ZVRA is a better buy in the short-term than QURE.

Price Growth

QURE (@Biotechnology) experienced а -2.32% price change this week, while ZVRA (@Biotechnology) price change was -0.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.22%. For the same industry, the average monthly price growth was +31.37%, and the average quarterly price growth was +12.88%.

Reported Earning Dates

QURE is expected to report earnings on Jul 31, 2025.

ZVRA is expected to report earnings on Aug 19, 2025.

Industries' Descriptions

@Biotechnology (+4.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
QURE($760M) has a higher market cap than ZVRA($492M). ZVRA YTD gains are higher at: 7.914 vs. QURE (-21.404). ZVRA has higher annual earnings (EBITDA): -60.3M vs. QURE (-138.01M). QURE has more cash in the bank: 409M vs. ZVRA (62.6M). ZVRA has less debt than QURE: ZVRA (61.8M) vs QURE (66.2M). ZVRA has higher revenues than QURE: ZVRA (40.6M) vs QURE (20.2M).
QUREZVRAQURE / ZVRA
Capitalization760M492M154%
EBITDA-138.01M-60.3M229%
Gain YTD-21.4047.914-270%
P/E RatioN/AN/A-
Revenue20.2M40.6M50%
Total Cash409M62.6M653%
Total Debt66.2M61.8M107%
FUNDAMENTALS RATINGS
QURE vs ZVRA: Fundamental Ratings
QURE
ZVRA
OUTLOOK RATING
1..100
5469
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
84
Overvalued
PROFIT vs RISK RATING
1..100
10066
SMR RATING
1..100
10099
PRICE GROWTH RATING
1..100
3940
P/E GROWTH RATING
1..100
9223
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

QURE's Valuation (79) in the Biotechnology industry is in the same range as ZVRA (84) in the null industry. This means that QURE’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's Profit vs Risk Rating (66) in the null industry is somewhat better than the same rating for QURE (100) in the Biotechnology industry. This means that ZVRA’s stock grew somewhat faster than QURE’s over the last 12 months.

ZVRA's SMR Rating (99) in the null industry is in the same range as QURE (100) in the Biotechnology industry. This means that ZVRA’s stock grew similarly to QURE’s over the last 12 months.

QURE's Price Growth Rating (39) in the Biotechnology industry is in the same range as ZVRA (40) in the null industry. This means that QURE’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's P/E Growth Rating (23) in the null industry is significantly better than the same rating for QURE (92) in the Biotechnology industry. This means that ZVRA’s stock grew significantly faster than QURE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
QUREZVRA
RSI
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
78%
Momentum
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
81%
MACD
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
78%
Advances
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
86%
Bearish Trend 11 days ago
78%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
69%
Bullish Trend 2 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
QURE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MLRRX12.090.07
+0.58%
NYLI Winslow Large Cap Growth Class R1
JARSX15.740.04
+0.25%
Easterly Global Real Estate R6
IHIFX5.90N/A
N/A
Macquarie High Income Fund Class R6
PIGCX29.13N/A
N/A
Putnam International Equity C
NBREX25.65N/A
N/A
Neuberger Berman M/C Intrinsic Val Tr

QURE and

Correlation & Price change

A.I.dvisor indicates that over the last year, QURE has been loosely correlated with NAMS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if QURE jumps, then NAMS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QURE
1D Price
Change %
QURE100%
-2.46%
NAMS - QURE
50%
Loosely correlated
+0.65%
HOOK - QURE
44%
Loosely correlated
-0.40%
AXON - QURE
42%
Loosely correlated
+1.82%
ABSI - QURE
40%
Loosely correlated
-3.51%
CRNX - QURE
39%
Loosely correlated
-1.22%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with CRNX. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then CRNX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
-3.02%
CRNX - ZVRA
39%
Loosely correlated
-1.22%
ATXS - ZVRA
38%
Loosely correlated
+2.94%
QURE - ZVRA
38%
Loosely correlated
-2.46%
DNTH - ZVRA
37%
Loosely correlated
-2.81%
EYPT - ZVRA
36%
Loosely correlated
-6.94%
More